Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
ARIAD Pharmaceuticals
ARIA
Healthcare
Biotechnology
"ARIAD Pharmaceuticals Inc is an oncology company. The Company is engaged in transforming the lives of cancer patients with breakthrough medicines. It commercializes & develops products and product candidates including Iclusig, Brigatinib, and AP32788."
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ARIA)
New Post
View:
Posts & Comments
Threaded Posts
(1)
•••
Carlos66
X
View Profile
View Bullboard History
Post by
Carlos66
on May 06, 2015 7:15pm
CNBC
Mentioned on CNBC's Fast Money as a takeout target now that an activist investor in Sarissa mgmt (Alex Denner) is on the BOD & who engineered the retirement of the president of the co.. Its
...more
(0)
•••
sam1221
X
View Profile
View Bullboard History
Post by
sam1221
on Jan 28, 2014 9:00pm
seems like an investment to me too..
Its been holding steady at 8 bucks ,,so i believe this is a point of resistance,,,,i am holding a few at 8.5o but am holding patiently,,,,its definetly going past 10.....my due deligence,,
(0)
•••
ablekaak
X
View Profile
View Bullboard History
Post by
ablekaak
on Jan 27, 2014 4:56pm
I am In
Been outta buying stocks for a while but I am back, and I like ARIA will wet my feet with this. I think somethin is about to move on this one
(0)
•••
EarningsImpact1
X
View Profile
View Bullboard History
Post by
EarningsImpact1
on Jul 26, 2013 11:04am
Very Insightful during Investor-and-Analyst-Meeting
Updates on clinical and safety data from the AP26113 trial & more.. [url=https://www.earningsimpact.com/Transcript/82369/ARIA/Ariad-Pharmaceuticals%2c-Inc----Investor-and-Analyst-Meeting
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Nanalysis Scientific Corp. Announces First Quarter 2024 Results
This Small-Cap Gold Stock Jumped Almost 50% on Friday